Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes.
about
Preconception counselling for women with epilepsy to reduce adverse pregnancy outcomePreconception counselling for women with epilepsy to reduce adverse pregnancy outcomeIntrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control studyThe Impact of Anti-Epileptic Drugs on Growth and Bone MetabolismLong-term consequences after exposure to antiepileptic drugs in utero.Managing epilepsy in women of childbearing age.Severe consequences of carbamazepine exposure in uteroAntiepileptic medication during pregnancy: does fetal genotype affect outcome?Cognitive/behavioral teratogenetic effects of antiepileptic drugs.Do lamotrigine and levetiracetam solve the problem of using sodium valproate in women with epilepsy?Postnatal onset of severe growth retardation after in utero exposure to carbamazepine and phenobarbital: a case report.Cognitive abilities and behaviour of children exposed to antiepileptic drugs in utero.Teratogenicity of Antiepileptic Drugs.Prenatal exposures associated with neurodevelopmental delay and disabilities.Foetal safety of old and new antiepileptic drugs.Treatment options in juvenile myoclonic epilepsy.Selegiline is an efficient and potent inducer for bone marrow stromal cell differentiation into neuronal phenotype.
P2860
Q24198152-40B314F7-2DAD-4B0B-B966-CAC7474C00D5Q24242734-B7B5AADE-2670-409D-BEAD-BCD65766F2F3Q24631492-9265F8B4-71D5-48C1-8589-BA74E14C3F10Q26739054-21760F8A-28A7-4A1B-B5EA-98BB511E208DQ33949257-D49F1D08-5CBF-4A0B-B3A3-8AAC591E6658Q34977403-B90D2F0B-B261-448B-9B29-4C832714B70AQ35983179-5A5C9C30-7F38-4F45-ADED-D18986C0712CQ36863422-540ACA30-D38B-4BBC-AF29-2AC1C617F4C0Q36998336-F265CEAF-BCD4-4767-A2A0-73181324EC14Q37186130-32E1ACA0-C0F5-4B89-8B32-B49F062EBEACQ37304362-588E5207-9A9E-4990-8FDC-876E99D6806AQ37345777-D2594E80-DDA4-49A7-B9D7-738FC7D6BD96Q37623101-BE3200D0-CC72-42DC-B054-039B291B01C2Q38077730-C04B9DE2-C0F9-47BA-BB17-0D22D039A3C0Q38578361-9123E215-F42D-4130-9BE2-F69A6E6CDAB2Q45383090-31681A57-F055-4337-BAF8-E65DEC811AA0Q46021744-1667C02F-95FA-4A68-AD97-93295CF8E119
P2860
Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 October 2005
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dysmorphic features: an import ...... etal anticonvulsant syndromes.
@en
Dysmorphic features: an import ...... etal anticonvulsant syndromes.
@nl
type
label
Dysmorphic features: an import ...... etal anticonvulsant syndromes.
@en
Dysmorphic features: an import ...... etal anticonvulsant syndromes.
@nl
prefLabel
Dysmorphic features: an import ...... etal anticonvulsant syndromes.
@en
Dysmorphic features: an import ...... etal anticonvulsant syndromes.
@nl
P2093
P2860
P356
P1476
Dysmorphic features: an import ...... etal anticonvulsant syndromes.
@en
P2093
J Clayton-Smith
Liverpool and Manchester Neurodevelopmental Study Group
P2860
P356
10.1136/ADC.2004.067421
P577
2005-10-20T00:00:00Z